Education
About Us
Working with TipRanks
Follow Us
Aldeyra Therapeutics (DE:137)
:137
137 Stock Chart & Stats
Day’s Range― - ―
52-Week Range€1.30 - €6.42
Previous CloseN/A
Volume0.00
Average Volume (3M)531.00
Market Cap
€139.24M
Enterprise Value€126.91M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.78
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding59,708,652
10 Day Avg. Volume542
30 Day Avg. Volume531
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-8.20
P/FCF Ratio0.00
Enterprise Value/Market Cap0.91
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.36
Forecast
1Y Price Target
€8.48Price Target Upside343.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Aldeyra Therapeutics News
PremiumCompany Announcements
Aldeyra Therapeutics Appoints Chip Clark to Board---
Bulls Say, Bears Say
Bulls Say
Drug Approval ProspectsAnalysts see an 85% probability of FDA approval for reproxalap, aligning with the FDA resubmission approval rates for novel drugs.
Financial PositionThe company has approximately $101M in cash and expects the remaining costs for the ongoing trials to be only around $6M, which keeps the company in a favorable financial position.
Partnership OpportunitiesThe outstanding option agreement with AbbVie addresses possible development and commercialization of reproxalap in the US market, which is seen as an upside with option execution potentially before approval.
Bears Say
Approval UncertaintyThe probability of success for Reproxalap has been decreased from 85% to 75%, reflecting increased uncertainty in the approval process.
Manufacturing ConcernsThere is a 15% probability of a manufacturing-related Complete Response Letter, which could jeopardize the option.
Regulatory ChallengesThe FDA has delayed the approval of Reproxalap due to concerns over trial results, which has pushed the expected drug launch out by a year.
---
Options Prices
Currently, No data available
---
Ownership Overview
18.96% Insiders
10.98%
Mutual Funds
26.56% Other Institutional Investors
33.95% Public Companies and
Individual Investors
137 FAQ
What was Aldeyra Therapeutics’s price range in the past 12 months?
Aldeyra Therapeutics lowest stock price was €1.30 and its highest was €6.42 in the past 12 months.
What is Aldeyra Therapeutics’s market cap?
Aldeyra Therapeutics’s market cap is €139.24M.
When is Aldeyra Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Aldeyra Therapeutics’s earnings last quarter?
Aldeyra Therapeutics released its earnings results on Mar 07, 2024. The company reported -€0.07 earnings per share for the quarter, beating the consensus estimate of -€0.098 by €0.027.
Is Aldeyra Therapeutics overvalued?
According to Wall Street analysts Aldeyra Therapeutics’s price is currently Undervalued.
Does Aldeyra Therapeutics pay dividends?
Aldeyra Therapeutics does not currently pay dividends.
What is Aldeyra Therapeutics’s EPS estimate?
Aldeyra Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aldeyra Therapeutics have?
Aldeyra Therapeutics has 59,708,652 shares outstanding.
What happened to Aldeyra Therapeutics’s price movement after its last earnings report?
Aldeyra Therapeutics reported an EPS of -€0.07 in its last earnings report, beating expectations of -€0.098. Following the earnings report the stock price went up 3.524%.
Which hedge fund is a major shareholder of Aldeyra Therapeutics?
Currently, no hedge funds are holding shares in DE:137
---
Aldeyra Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€8.48 (343.86% Upside)
€8.48 (343.86% Upside)
Blogger Sentiment
Bullish
DE:137 Sentiment 70%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $4.8M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-32.48%
12-Months-Change
Fundamentals
Return on Equity
-58.54%
Trailing 12-Months
Asset Growth
-29.48%
Trailing 12-Months
Company Description
Aldeyra Therapeutics
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
---
137 Stock 12 Month Forecast
Average Price Target
€8.48
▲(343.86% Upside)
Technical Analysis
Nektar Therapeutics
―
Larimar Therapeutics
―
Kodiak Sciences
―
RAPT Therapeutics
―
Nkarta
―
Best Analysts Covering 137
1 Year
1 Year Success Rate
6/12 ratings generated profit
1 Year Average Return
+17.09%
reiterated a buy rating 26 days ago
Copying Catherine Novack's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +17.09% per trade.
---